DAWN

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with life-threatening diseases. The company focuses on genomically defined cancers, with particular emphasis on pediatric and young adult patients. Day One's lead program, tovorafenib, is a type II pan-RAF inhibitor being developed for pediatric low-grade glioma and other solid tumors. Based in Brisbane, California, the company aims to address cancers driven by specific genetic alterations with precision medicines.